Fibrocell Science Inc. (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The firm currently has a $0.75 target price on the stock. Zacks Investment Research’s price objective indicates a potential upside of 7.25% from the company’s current price.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Separately, Canaccord Genuity reaffirmed a “buy” rating and set a $1.50 price target on shares of Fibrocell Science in a research report on Sunday, August 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.65.

Fibrocell Science (NASDAQ:FCSC) opened at 0.6993 on Monday. Fibrocell Science has a 52-week low of $0.52 and a 52-week high of $6.18. The company’s market cap is $30.70 million. The stock has a 50 day moving average of $0.67 and a 200-day moving average of $1.15.

Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Fibrocell Science had a negative return on equity of 215.38% and a negative net margin of 7,362.25%. On average, analysts forecast that Fibrocell Science will post ($0.35) EPS for the current year.

Several large investors have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Fibrocell Science by 31.4% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 250,803 shares of the company’s stock worth $288,000 after buying an additional 59,926 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Fibrocell Science by 54.6% in the second quarter. Janney Montgomery Scott LLC now owns 172,932 shares of the company’s stock worth $199,000 after buying an additional 61,050 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Fibrocell Science during the second quarter worth about $111,000. Finally, Oxford Asset Management boosted its stake in shares of Fibrocell Science by 60.2% in the second quarter. Oxford Asset Management now owns 313,959 shares of the company’s stock worth $361,000 after buying an additional 118,007 shares in the last quarter. Institutional investors own 61.64% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

5 Day Chart for NASDAQ:FCSC

Receive News & Stock Ratings for Fibrocell Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc. and related stocks with our FREE daily email newsletter.